Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2256 articles about Gilead Sciences, Inc.
-
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
7/24/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial.
-
Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million
7/24/2023
Cognizant (NASDAQ: CTSH) today announced an expansion of its relationship with Gilead Sciences (NASDAQ: GILD). Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases.
-
The infectious diseases market is expected to reach $150 billion in sales by 2029, with three pharma giants reaping most of its benefits, according to data analytics and consultancy GlobalData.
-
Despite the lifting of the FDA’s partial clinical hold, Gilead will discontinue magrolimab’s development in higher-risk myelodysplastic syndromes after a Phase III study met the bar for futility.
-
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
7/21/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis.
-
Pharmas, advocacy groups and regulatory bodies have made moves to put each other in legal crosshairs in 2023. Follow along with BioSpace’s Lawsuit Tracker to see what’s piling up on the docket.
-
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
7/20/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care.
-
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
7/20/2023
The Center for Disease Analysis Foundation announced that it received an $8 million grant from Gilead Sciences as part of Gilead’s Relink grant program.
-
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
7/19/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 12th International AIDS Society Conference on HIV Science (IAS 2023), taking place in Brisbane, Australia, and virtually, from July 23-26, 2023.
-
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
7/14/2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes.
-
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
7/14/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury ® (remdesivir).
-
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
7/13/2023
Partnership Aims to Accelerate the Development of Dispersible Pediatric HIV Medicines Gilead Sciences, Inc. is pleased to announce two public-private partnerships.
-
GILEAD SCIENCES AND IAS – THE INTERNATIONAL AIDS SOCIETY – HONOUR HEALTHCARE PROVIDERS GLOBALLY WHO CHAMPION STIGMA-FREE HIV SERVICES
7/5/2023
IAS – the International AIDS Society – in partnership with Gilead Sciences, announced 18 Champions of the 2023 Me and My Healthcare Provider (MMHCP) campaign from Brazil, Hong Kong, Mexico and Taiwan.
-
The verdict, rendered by a California jury on Friday, found that the companies did not engage in an anticompetitive conspiracy to delay generic versions of HIV PreEP medicines.
-
Topline results for its Daiichi Sankyo-partnered antibody-drug conjugate showed statistically significant improvement. However, AstraZeneca shares dropped around 6% in early Monday trading.
-
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
6/23/2023
Gilead Sciences, Inc. announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® for the treatment of adults with chronic hepatitis delta infection.
-
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
6/23/2023
Gilead Receives CHMP Positive Opinion for Trodelvy ® in Pre-Treated HR+/HER2- Metastatic Breast Cancer.
-
The government asked a federal judge to overturn a verdict in which a Delaware jury ruled in favor of Gilead, deciding that its preventative HIV drugs Truvada and Descovy did not infringe on its patents.
-
Asian American Women Engineers Find Community and Purpose at Gilead
6/14/2023
When Vicky Choi began her career as an engineer, she noticed that women and Asian people overall were well represented in the field - but that Asian women weren't reflected in upper management and leadership positions.
-
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
6/14/2023
Gilead Sciences, Inc. announced new data to be presented at the European Association for the Study of the Liver Congress 2023, June 21-24, 2023.